

Special Issue

New Insights Toward the Development of Novel Inhibitors of *S. aureus* and *P. aeruginosa* Factors

Message from the Guest Editors

Staphylococcus aureus and *Pseudomonas aeruginosa*, both classified among the ESKAPE pathogens, represent a growing public health concern due to their increasing multidrug resistance and the limited development of new antimicrobial therapies. *P. aeruginosa* possesses three interconnected quorum-sensing (QS) circuits regulated by MvfR, LasR, and RhlR, which are central to *P. aeruginosa*'s virulence and antibiotic resistance mechanisms. *S. aureus* infections pose a significant challenge due to the involved virulence factors and increasing antibiotic resistance. This Special Issue seeks manuscript submissions that further our understanding of antimicrobial resistance in the coinfection of *S. aureus* and *P. aeruginosa*, as well as new approaches toward the development of novel strategies to inhibit *S. aureus* and *P. aeruginosa* components. Contributions on combination therapy, anti-biofilm strategies, or targeting microbial interactions and host response are especially encouraged.

Guest Editors

Dr. Que Chi Truong-Bolduc

Dr. Leon G. Leanse

Prof. Dr. Hidemasa Nakaminami

Dr. Chun-Hsing Liao

Deadline for manuscript submissions

31 December 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/245075

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)